Second-line Treatment Patterns and Outcomes in Advanced HCC after Progression on Atezolizumab/Bevacizumab
JHEP REPORTS（2025）
Key words
Hepatocellular carcinoma,atezolizumab,bevacizumab,second-line therapy,immune checkpoint inhibitors,immunotherapy,tyrosine kinase inhibitors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined